PLUR Key Statistics, Chart & Performance
The current stock price of PLUR is 3.28 USD. In the past month the price increased by 0.92%. In the past year, price decreased by -39.82%.
PLUR Latest News, Press Relases and Analysis
PLUR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About PLUR
Company Profile
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.
Company Info
PLURI INC
Matam Advanced Technology Park, Building No. 5
Haifa IL
Employees: 106
Phone: 972747108600
PLURI INC / PLUR FAQ
Can you describe the business of PLURI INC?
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.
What is the stock price of PLURI INC today?
The current stock price of PLUR is 3.28 USD. The price increased by 0.61% in the last trading session.
Does PLUR stock pay dividends?
PLUR does not pay a dividend.
How is the ChartMill rating for PLURI INC?
PLUR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of PLUR stock?
PLURI INC (PLUR) has a market capitalization of 30.34M USD. This makes PLUR a Nano Cap stock.
Can you provide the upcoming earnings date for PLURI INC?
PLURI INC (PLUR) will report earnings on 2026-02-09.
Can you provide the ownership details for PLUR stock?
You can find the ownership structure of PLURI INC (PLUR) on the Ownership tab.
PLUR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PLUR. When comparing the yearly performance of all stocks, PLUR is a bad performer in the overall market: 92.18% of all stocks are doing better.
PLUR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLUR. PLUR has a bad profitability rating. Also its financial health evaluation is rather negative.
PLUR Financial Highlights
Over the last trailing twelve months PLUR reported a non-GAAP Earnings per Share(EPS) of -3.1. The EPS increased by 24.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PLUR Forecast & Estimates
7 analysts have analysed PLUR and the average price target is 12.24 USD. This implies a price increase of 273.17% is expected in the next year compared to the current price of 3.28.
For the next year, analysts expect an EPS growth of 12.2% and a revenue growth 63.28% for PLUR